Diligence memo · auto-generated · as of July 3, 2026

MedPro Investments LLC

MedPro Investments LLC looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

MedPro Investments LLC operates in Biotechnology, based in LEXINGTON.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

MedPro Investments LLC has raised $25M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $25M on 2010-09-01.

Most recent recorded round closed around 2010-09-01.

Valuation (modeled)modeled

Provath models MedPro Investments LLC at approximately $992M (range $50M–$3.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.52× the median modeled value of Series B Biotechnology companies in 2010–2012 (48 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Last raise 15.8 yr ago; this sector typically re-raises about every 14 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 72% of Biotechnology peers (4293 compared).

Modeled value ranks above 89% of those peers.

Closest niche peers: Redpoint Bio CORP, Cardiaq Valve Technologies Inc, Visterra, Inc., Celltex Therapeutics Corp, Crown Bioscience, Inc.

Peoplefiled

4 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.